Ron Hsu
InvestorPrincipal at Abingworth
About
Ron Hsu joined Abingworth in July 2026 as part of the Clinical Co-Development team, where he evaluates new investment opportunities and supports existing investments. Before Abingworth, he spent a year at portfolio company Launch Therapeutics assessing clinical co-development opportunities, and earlier led public and private biopharma investments at the Qatar Investment Authority and worked as a research analyst covering public biopharmaceutical companies at Millennium Management and Artisan Partners. He holds an MD from New York Medical College and a BA in Biochemistry from Harvard College.
Invests in
Biotech
Colleagues at Abingworth
Alex Asquith
Counsel at Abingworth
Amit Khasgiwala
Investment Professional at Innovatus Capital Partners
Andrew Sinclair
Managing Director, Head of Publics & Late Stage at Abingworth
Ankur Shah
Vice President, CCD at Abingworth
Anna Slezak
Senior Associate at Abingworth
Bali Muralidhar
Global Head of Life Sciences & CIO at Abingworth
Carlos Paya
Venture Partner at Ysios Capital
Carlos Paya
Venture Partner at Abingworth
Frequently asked questions
- Who is Ron Hsu?
- Ron Hsu joined Abingworth in July 2026 as part of the Clinical Co-Development team, where he evaluates new investment opportunities and supports existing investments. Before Abingworth, he spent a year at portfolio company Launch Therapeutics assessing clinical co-development opportunities, and earlier led public and private biopharma investments at the Qatar Investment Authority and worked as a research analyst covering public biopharmaceutical companies at Millennium Management and Artisan Partners. He holds an MD from New York Medical College and a BA in Biochemistry from Harvard College.
- Where does Ron Hsu work?
- Ron Hsu is Principal at Abingworth.
- What does Ron Hsu invest in?
- Ron Hsu invests in Biotech.